MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
2024年10月8日 - 8:30PM
MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company
pioneering the development of allogeneic off-the-shelf, invariant
natural killer T (iNKT) cell therapies and Autonomous Therapeutics,
Inc. (Autonomous), a leader developing first-in-class,
disease-activated RNA medicines, announced a research collaboration
aimed at effectively targeting and treating metastatic tumors.
This collaboration will leverage Autonomous’
precision encrypted RNA™ (encRNA) technology and MiNK’s innovative
iNKT cell therapies, MiNK-215 and agenT-797. The companies will
evaluate these technologies in state-of-the-art metastatic solid
tumor models. The goal is to develop novel therapies that
effectively target metastatic cancer cells in patients while
avoiding healthy cells—a challenge that existing cancer medicines
have not been able to overcome. Based on the results, the companies
plan to launch a Phase 1 clinical trial in patients with
treatment-refractory metastatic solid tumors, including
microsatellite stable (MSS) colorectal cancers.
“This collaboration underscores the unique
potential of both native and engineered iNKT cells, allowing us to
explore cutting-edge approaches that could significantly enhance
clinical responses and deliver better outcomes for patients,” said
Dr. Jennifer Buell, President and Chief Executive Officer at MiNK.
“MiNK-215 and agenT-797 are novel cell therapies designed to
overcome the limitations of traditional immune checkpoint
inhibitors. Recent preclinical models of MSS colorectal cancer with
metastatic liver disease demonstrated that these iNKT cells have
the potential to eliminate tumor cells effectively. By combining
them with Autonomous Therapeutics' engineered RNA technology, we
are confident that we can unlock even greater therapeutic
possibilities and continue advancing our mission to transform the
landscape of cell therapy.”
Dr. Ariel Weinberger, Chief Executive Officer of
Autonomous, added: “This exciting collaboration leverages the
platform capabilities of our next-generation encrypted RNA
technology and MiNK’s unique allogeneic cell therapy platform.
AT313 is a preclinical encRNA candidate developed at Autonomous to
enable the precision targeting of solid tumors, via
cancer-activated therapeutic protein translation. Our aim is to
develop novel medicines that pinpoint tumor cells in patients—by
sensing and targeting the aberrant molecular signatures that define
cancer replication. This would enable us to eliminate cancer cells
in patients while sparing healthy and immune cells. It would also
eliminate dose-limiting toxicities common to existing oncology
medicines while significantly enhancing therapeutic efficacy—to
dramatically improve Stage IV patient outcomes.”
About MiNK-215
MiNK-215 is an investigational, off-the-shelf
cellular immunotherapy, specifically designed to target immune
resistance mechanisms and promote a potent anti-cancer immune
response. Engineered to express CAR targeting the Fibroblast
Activating Protein (FAP) protein prevalent in stromal cells within
the tumor microenvironment, MiNK-215 also integrates soluble IL-15
for enhanced persistence (Michelet X et al, SITC 2022; Shan K et
al, AACR 2023; Dijk MV et al, CICON 2023). In preclinical models
resistant to immune checkpoint inhibitors, MiNK-215 has
demonstrated remarkable efficacy, not only in eliminating tumor
cells and FAP+ immune-suppressive cells but also facilitating the
infiltration and persistence of proinflammatory cytotoxic T cells
crucial for effective tumor elimination.
About agenT-797
AgenT-797 is an investigational, off-the-shelf
immune cell therapy product by MiNK Therapeutics, possessing
anti-viral and immune-modulating properties. In a Phase 1 trial
involving 54 patients with heavily pre-treated solid tumors,
agenT-797 appears to overcome resistance to immune checkpoint
inhibitors, with durable disease stabilization in multiple solid
tumors and a confirmed response in chemotherapy and anti-PD-1
refractory gastric cancer (Carneiro et al, 2024 Oncogene).
agenT-797 is being evaluated in an investigator sponsored Phase 2
trial in 2L gastric cancer, led by Dr. Yelena Janjigian, Chief of
GI Oncology at Memorial Sloan-Kettering Cancer Center and supported
by Stand Up to Cancer.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage
biopharmaceutical company pioneering the discovery, development,
and commercialization of allogeneic invariant natural killer T
(iNKT) cell therapies to treat cancer and other immune-mediated
diseases. MiNK is advancing a pipeline of both native and next
generation engineered iNKT programs, with a platform designed to
facilitate scalable and reproducible manufacturing for
off-the-shelf delivery. The company is headquartered in New York,
NY. For more information, visit https://minktherapeutics.com/ or
@MiNK_iNKT. Information that may be important to investors will be
routinely posted on our website and social media channels.
About Autonomous Therapeutics,
Inc.
Autonomous Therapeutics is pioneering a new class
of RNA medicines (encRNA) for difficult-to-treat indications in
oncology and infectious disease. Autonomous has developed a
proprietary pipeline of more than 10 encRNA candidates targeting
indications from pandemic influenza to metastatic cancers. The
company’s encRNA pipeline includes next-generation immunotherapies
such as AT313, a cancer-activated RNA prodrug designed to precisely
eliminate solid tumor cells. Autonomous’ partners and funders have
included: the Defense Advanced Research Projects Agency (DARPA),
the National Institutes of Health (NIH), the Office of the
Secretary of Defense (OSD), Third Kind Venture Capital (3kVC), and
BLUE KNIGHT™, a joint initiative between the Biomedical Advanced
Research and Development Authority (BARDA) and Johnson &
Johnson Innovation – JLABS.
About encrypted RNA™
encRNA is a new class of RNA invented at Autonomous
to enable the development of precision medicines against virtually
any disease driven by aberrant nucleic acid expression or protein
translation. Autonomous’ encRNA therapeutics leverage the molecular
signatures of a targeted disease as intracellular logic gates—to
drive precision therapeutic protein translation in targeted cells.
Each encRNA candidate is designed to differentiate between healthy
and diseased cells across a patient and to translate therapeutic
proteins solely in diseased cells. encRNA candidates are modular
and can be programmed with multiple logic gates for potential
patient-specific sensitivity and specificity. In proof-of-concept
studies, Autonomous has demonstrated the preclinical safety and
efficacy of encRNA candidates in animal models, with the potential
to completely eradicate immunologically “cold” solid tumors via
precision immunotherapy.
Forward Looking Statements
This press release contains forward-looking
statements that are made pursuant to the safe harbor provisions of
the federal securities laws, including statements regarding the
therapeutic potential, anticipated benefit, plans and timelines of
iNKT cells and encrypted RNA, as well as the collaboration between
MiNK and Autonomous Therapeutics. These forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially. These forward-looking statements are
subject to risks and uncertainties, including the factors described
under the Risk Factors section of the most recent Form 10-K, Form
10-Q and the S-1 Registration Statement filed with the SEC.
MiNK cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
MiNK and Autonomous undertake no obligation to update or revise the
statements, other than to the extent required by law. All
forward-looking statements are expressly qualified in their
entirety by this cautionary statement.
MiNK Investor Contact
917-362-1370
investor@minktherapeutics.com
MiNK Media Contact
781-674-4428
communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
過去 株価チャート
から 12 2024 まで 1 2025
MiNK Therapeutics (NASDAQ:INKT)
過去 株価チャート
から 1 2024 まで 1 2025